Richard Chesworth

Chief Scientific Officer

Richard has more than 20 years of experience in the pharmaceutical and biotechnology industry and has contributed to the research and development programs of nine different compounds entering clinical trials including Tazverik™ which was recently approved for both epitheloid sarcoma and relapsed/refractory follicular lymphoma. Prior to joining K...

Roles at Kymera Therapeutics

  • Chief Scientific Officer

    Current role

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.